Neuronal and astrocytic differentiation from Sanfilippo C syndrome iPSCs for disease modeling and drug development

dc.contributor.authorBenetó, Noelia
dc.contributor.authorCozar, Mónica
dc.contributor.authorCastilla-Vallmanya, Laura
dc.contributor.authorZetterdahl, Oskar G.
dc.contributor.authorSacultanu, Madalina
dc.contributor.authorSegur-Bailach, Eulalia
dc.contributor.authorGarcía-Morant, María
dc.contributor.authorRibes Rubió, Maria Antònia
dc.contributor.authorAhlenius, Henrik
dc.contributor.authorGrinberg Vaisman, Daniel Raúl
dc.contributor.authorVilageliu i Arqués, Lluïsa
dc.contributor.authorCanals Montferrer, Isaac
dc.date.accessioned2021-02-25T17:51:23Z
dc.date.available2021-02-25T17:51:23Z
dc.date.issued2020-02-28
dc.date.updated2021-02-25T17:51:23Z
dc.description.abstractSanfilippo syndrome type C (mucopolysaccharidosis IIIC) is an early-onset neurodegenerative lysosomal storage disorder, which is currently untreatable. The vast majority of studies focusing on disease mechanisms of Sanfilippo syndrome were performed on non-neural cells or mouse models, which present obvious limitations. Induced pluripotent stem cells (iPSCs) are an efficient way to model human diseases in vitro. Recently developed transcription factor-based differentiation protocols allow fast and efficient conversion of iPSCs into the cell type of interest. By applying these protocols, we have generated newneuronal and astrocyticmodels of Sanfilippo syndrome using our previously established disease iPSC lines. Moreover, our neuronal model exhibits disease-specific molecular phenotypes, such as increase in lysosomes and heparan sulfate. Lastly, we tested an experimental, siRNA-based treatment previously shown to be successful in patients' fibroblasts and demonstrated its lack of efficacy in neurons. Our findings highlight the need to use relevant human cellular models to test therapeutic interventions and shows the applicability of our neuronal and astrocyticmodels of Sanfilippo syndrome for future studies on disease mechanisms and drug development.
dc.format.extent15 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec699336
dc.identifier.issn2077-0383
dc.identifier.pmid32121121
dc.identifier.urihttps://hdl.handle.net/2445/174369
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/jcm9030644
dc.relation.ispartofJournal of Clinical Medicine, 2020, vol. 9, num. 644
dc.relation.urihttps://doi.org/10.3390/jcm9030644
dc.rightscc-by (c) Benetó, Noelia et al., 2020
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Genètica, Microbiologia i Estadística)
dc.subject.classificationMalalties del sistema nerviós
dc.subject.classificationTerapèutica
dc.subject.classificationMalalties hereditàries
dc.subject.otherNervous system Diseases
dc.subject.otherTherapeutics
dc.subject.otherGenetic diseases
dc.titleNeuronal and astrocytic differentiation from Sanfilippo C syndrome iPSCs for disease modeling and drug development
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
699336.pdf
Mida:
2.53 MB
Format:
Adobe Portable Document Format